Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus recommendation of “Buy” from the seventeen ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $284.00.

Several brokerages have recently issued reports on ASND. Wells Fargo & Company lifted their price objective on Ascendis Pharma A/S from $322.00 to $330.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 21st. Wolfe Research assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 price objective on the stock. Stifel Nicolaus set a $325.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday. Finally, Wedbush increased their target price on Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a report on Thursday.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $218.10 on Friday. The firm has a market capitalization of $13.52 billion, a PE ratio of -49.57 and a beta of 0.44. Ascendis Pharma A/S has a 1 year low of $124.06 and a 1 year high of $242.00. The firm’s 50-day moving average is $214.64 and its two-hundred day moving average is $204.49.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $250.71 million for the quarter, compared to analyst estimates of $246.91 million. Analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC purchased a new position in shares of Ascendis Pharma A/S during the second quarter worth about $166,367,000. Wellington Management Group LLP grew its stake in Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after buying an additional 880,836 shares during the last quarter. Principal Financial Group Inc. increased its position in Ascendis Pharma A/S by 2,722.9% during the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company’s stock worth $157,791,000 after buying an additional 765,561 shares during the period. Vestal Point Capital LP lifted its stake in Ascendis Pharma A/S by 200.0% in the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after buying an additional 400,000 shares during the last quarter. Finally, Spyglass Capital Management LLC purchased a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $77,267,000.

Ascendis Pharma A/S News Summary

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Strong revenue / product momentum: Ascendis reported Q4 revenue of $290.3M (above consensus) and highlighted robust YORVIPATH sales and growth momentum on the earnings call. This supports the company’s commercial trajectory. Read More.
• Positive Sentiment: Analyst upgrade / higher price target: Wedbush raised its price target from $240 to $273 and maintained an Outperform rating, implying ~25% upside from current levels and signaling analyst confidence in longer-term upside. Read More.
• Neutral Sentiment: Full earnings disclosure / transcripts available: Multiple transcripts and call highlights (TipRanks, Seeking Alpha, Yahoo) provide detail on guidance, commercialization cadence and pipeline positioning — useful for investors doing deeper due diligence but not immediate catalysts. Read More. • Read More.
• Neutral Sentiment: Short interest data shows no meaningful change (reported as zero in recent filings), so short-position flow does not appear to be a driving factor today. (Data items reported by market trackers.)
• Negative Sentiment: Big EPS miss: Ascendis reported GAAP EPS of ($0.64) vs. consensus $0.13 — a material miss that weighs on near-term sentiment despite revenue strength. Investors often punish earnings misses even when sales are growing. Read More.
• Negative Sentiment: Competitive risk in achondroplasia: Broader sector news (BridgeBio moves) has shifted the competitive landscape for achondroplasia treatments, pressuring peers including Ascendis and BioMarin. That dynamic is a headline-driven negative for the stock. Read More.
• Negative Sentiment: Conflicting coverage on revenue vs. estimates: Some outlets reported the quarter missed revenue expectations despite strong YORVIPATH uptake, adding short-term noise and uncertainty around street estimates. Read More.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.